Attendees can expect insights on advancements in glaucoma care, myopia management, dry eye treatments, emerging technologies, ocular disease myths, oral medications, the impact of obesity on ocular health, and more at the Southeastern Congress of Optometry (SECO) 2025.
The Southeastern Congress of Optometry (SECO) 2025 will be hosted in Atlanta, Georgia, from February 26 to March 2.
The future of glaucoma care, myopia management, and dry eye treatments are some of the main topics attendees can expect insights in at this year’s Southeastern Congress of Optometry (SECO) 2025, hosted in Atlanta, Georgia, from February 26 to March 2.1
Each morning from February 27 to March 1 will feature hot topic breakfasts featuring a panel of experts, each focusing on predictions and overviews of different eye care spaces (glaucoma, myopia, and dry eye).
Additionally, experts will explore the expansion of eye care overall during the event’s keynote presentation, featuring Julie Rodman, OD, MSc, FAAO, chief of the Fort Lauderdale Eye Care Institute, and Lawrence Woodard, MD, medical director of Omni Eye Services.2 This discussion will explore groundbreaking advancements in eye care, including artificial intelligence (AI), wearable tech, diagnostics, pharmaceuticals, and surgical innovations. Attendees should expect to gain insights into emerging technologies shaping the future of optometry and ophthalmology.
To bridge the misinformation gap, attendees can attend a session debunking myths about ocular diseases, presented by Bobby Saenz, II, OD, MS, FAAO, co-founder of LASIK & Cataract San Antonio and an adjunct assistant professor at the Rosenberg School of Optometry. Saenz will tackle myths about posterior segment diseases and explore the latest research challenging conventional treatments in ocular disease management.
Saenz will also present on the use of oral medications in managing various ocular conditions, with a focus on treatment strategies, emerging updates, and clinical applications. Attendees will gain insights into the use of antibiotics, antifungals, steroids, and non-steroidal anti-inflammatory drugs in optometric practice.
Providers who attend the meeting can pop in multiple presentations directed at improving managed care practices within ophthalmic facilities, including how to better incorporate AI systems and tools into practice, how to deal with difficult people and cultivate your care team, how to increase profit margins and quality of life with independent and luxury brands, overcoming language barriers in optometric practices, and more.1
Additionally, Lynn Eric Lawrence, Sr, MSOL, CPOT, ABOC, COA, OSC, leadership and staff development consultant, national lecturer, and an ophthalmic technician for Mills Eye and Facial Plastic Surgery, will lead a session on effectively communicating provider-directed dry eye treatments to patients.2 Sponsored by the National Academy of Opticianry and SECO International, this course will cover ocular anatomy, ocular surface disease, contributing factors, treatment options, and industry trends. Attendees will gain valuable insights into in-office and at-home treatments, product recommendations, and best practices for patient education and post-operative care.
Several workshops on laser therapy will be available, as well as presentations on what optometrists should know about prescreening techniques, cataract surgery, prescribing opiates for ocular pain, prescribing medications for pregnant patients with ophthalmic conditions, the growth of anti-vascular endothelial growth factor medications, and the relationship between a patient’s sight and dyslexia.1
On the last day of the meeting, Breanne McGhee, OD, PhD, MEd, primary care and pediatric optometrist at Ochsner Health, will present on the obesity epidemic in the US and its impact on systemic and ocular health.2 The session will explore the role of optometrists in identifying obesity risks, addressing social determinants of health, and understanding obesity-related diseases. Attendees will gain insights into treatment approaches, including lifestyle modifications, medical management, and surgical interventions.
References
1. Official course listing. SECO 2025. Accessed February 25, 2025. https://heyzine.com/flip-book/14015d277f.html#page/1
2. Course finder. SECO 2025. Accessed February 25, 2025. https://attendseco.com/course-finder/
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More